COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,893 Articles (22,568 medRxiv, 8,325 bioRxiv)

Most recent first Previous |  Page 1167: Articles 11661-11670  | Next

Clinical evaluation of a RT-LAMP SARS-CoV-2 test for the Point-Of-Care, rapid, low-cost, integrating sample solid phase extraction and on which reagents are lyophilized.
Coz, E., Garneret, P., Martin, E., Freitas do Nascimento, D., Vilquin, A., Hoinard, D., Feher, M., Grassin, Q., Vanhomwegen, J., Manuguerra, J.-C., Mukherjee, S., Olivo-Marin, J.-C., Brient-Litzler, E., Merzoug, M., collin, e., Tabeling, P., rossi, b.
10.1101/2021.10.03.21264480 — Posted: 2021-10-04
Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2
Badano, M. N., Sabbione, F., Keitelman, I., Pereson, M. J., Aloisi, N., Colado, A., Ramos, V., Ortiz Wilczynski, J. M., Pozner, R., Castillo, L., Wigdorovitz, G., E de Bracco, M. M., Fink, S., Chuit, R., Bare, P.
10.1101/2021.10.02.21264432 — Posted: 2021-10-04
Using conditional inference to quantify interaction effects of socio-demographic covariates of US COVID-19 vaccine hesitancy
Shen, K., Kejriwal, M.
10.1101/2021.10.02.21264456 — Posted: 2021-10-04
COVID-19 Vaccine: Newspaper Coverage of the side effects of the vaccine in Nigeria
Soyemi, K. V., Ewedairo, O. A., Olomofe, C. O.
10.1101/2021.10.02.21264454 — Posted: 2021-10-04
Why a Globally Fair COVID-19 Vaccination? An Analysis based on Agent-Based Simulation
Zia, K.
10.1101/2021.10.03.21264494 — Posted: 2021-10-04
Unique Peptide Signatures Of SARS-CoV-2 Against Human Proteome Reveal Variants' Immune Escape And Infectiveness
Pierros, V., Kontopodis, E., Stravopodis, D., Tsangaris, G. T.
10.1101/2021.10.03.462911 — Posted: 2021-10-04
COVID-19 data reporting systems in Africa reveal insights for pandemic preparedness
Judson, S. D., Torimiro, J., Pigott, D. M., Maima, A., Mostafa, A., Samy, A., Rabinowitz, P., Njabo, K.
10.1101/2021.10.01.21264385 — Posted: 2021-10-04
In Vitro Activity of Cysteamine Against SARS-CoV-2 Variants Alpha, Beta, Gamma and Delta
Thoene, J. G., Gavin, R. F., Towne, A., Wattay, L., Ferrari, M. G., Pal, R.
10.1101/2021.10.02.462862 — Posted: 2021-10-04
Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern
Almanza, G., Kouznetsova, V., Clark, A. E., Olmedillas, E., Castro, A., Tsigelny, I. F., Wu, Y., Gao, G. F., Ollmann Saphire, E., Carlin, A. F., Zanetti, M.
10.1101/2021.10.01.462840 — Posted: 2021-10-04
Frequency of surveillance testing necessary to reduce transmission of the Delta variant of SARS-CoV-2
Elbanna, A., Goldenfeld, N.
10.1101/2021.10.01.21262806 — Posted: 2021-10-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).